Filtered By:
Vaccination: Pneomococcal Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 303 results found since Jan 2013.

Pulmonary Arterial Hypertension: Unraveling Its Impact On Heart And Lungs
Conclusion Navigating the complexities of Pulmonary Arterial Hypertension (PAH) might seem daunting. However, with the right knowledge and proactive approach, it’s possible to manage the condition and maintain a good quality of life. PAH, a unique type of high blood pressure affecting the arteries in the lungs, can put extra strain on the heart. Over time, this can lead to heart failure. The condition’s root cause may vary, from genetic factors to other health issues like heart defects, liver disease, or autoimmune diseases. Remember, sometimes the cause remains unknown, resulting in idiopathic pulmonary ...
Source: The EMT Spot - July 19, 2023 Category: Emergency Medicine Authors: Michael Rotman, MD, FRCPC, PhD Tags: Blood Pressure Source Type: blogs

What can traditional plant therapy do in the face of Covid-19? Examples from traditional Chinese medicine
Conclusion: TCM can obtain obvious curative effect in symptomatic treatment, has strong anti-inflammatory effect, and can effectively reduce symptoms and patients ' pain.Keywords: COVID-19; traditional plant therapy; Qingfei Paidu decoction.
Source: African Health Sciences - July 13, 2023 Category: African Health Authors: Dandan Song, Qian Deng, Hualiang Chen Source Type: research

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults  ≥65 years old
CONCLUSIONS: Safety and immunogenicity of coadministered PCV20 and BNT162b2 were similar to those of PCV20 or BNT162b2 administered alone, suggesting that the 2 vaccines may be coadministered.TRIAL REGISTRATION: ClinicalTrials.gov, NCT04887948.PMID:37244809 | PMC:PMC10165018 | DOI:10.1016/j.vaccine.2023.05.002
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: David Fitz-Patrick Mariano Young Kari Yacisin Kathleen McElwee Todd Belanger Kelly Belanger Yahong Peng Dung-Yang Lee William C Gruber Daniel A Scott Wendy Watson Source Type: research

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults
CONCLUSION: Most of the adverse events observed from RTS,S/AS01 and RTS,S/AS02 malaria vaccines were reported in the control group and shared by other vaccines. Hence, the authors concluded that both RTS,S/AS01 and RTS,S/AS02 malaria vaccines are safe.PMID:36941908 | PMC:PMC10024506 | DOI:10.2147/CPAA.S400155
Source: Clinical Pharmacology: Advances and Applications - March 21, 2023 Category: Allergy & Immunology Authors: Wubetu Yihunie Bekalu Kebede Bantayehu Addis Tegegne Melese Getachew Dehnnet Abebe Yibeltal Aschale Habtamu Belew Bereket Bahiru Source Type: research